Design Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,077,708 201 906 Not applicable”
Shareholder Votes
Design Therapeutics, Inc. shareholders approved Election of Director at the 2026-06-09 meeting.
“Proposal 1. Election of Director The Company’s stockholders elected the one person listed below as a Class II director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or, if sooner, until his death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Simeon George, M.D. 29,205,208 7,608,724 13,264,883”
Earnings Releases
Design Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income Net loss was $17.6 million for the quarter ended March 31, 2026..
“Net loss was $17.6 million for the quarter ended March 31, 2026.”
Earnings Releases
Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2025.
“On March 9, 2026, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025.”
Earnings Releases
Design Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $11.1 million.
“Net loss was $11.1 million for the quarter ended March 31, 2024.”
Earnings Releases
Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2023.
“On March 19, 2024, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.”
Earnings Releases
Design Therapeutics, Inc. reported third quarter 2023 results: net income Net loss was $15.8 million for the quarter ended September 30, 2023.. Guidance reaffirmed.
“Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.”
Simeon George was appointed as Lead Independent Director at Design Therapeutics, Inc..
“the Board appointed Simeon George, M.D., as the Company’s lead independent director”
Pratik Shah was appointed as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..
“On August 25, 2023, the Board appointed Pratik Shah, Ph.D., as the Company’s President, Chief Executive Officer and principal financial officer.”
João Siffert resigned as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..
“agreed to the resignation of Dr. Siffert from all offices of the Company and from the Board, effective immediately”
Earnings Releases
Design Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the quarter ended June 30, 2023..
“Net loss was $19.9 million for the quarter ended June 30, 2023.”
Shareholder Votes
Design Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 52,499,051 437 123,262 0”
Shareholder Votes
Design Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-05-31 meeting.
“The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Simeon George, M.D. 47,533,466 1,741,637 3,347,647 Arsani William, M.D. 48,972,541 302,562 3,347,647 Deepa Prasad 48,988,793 286,310 3,347,647”
Earnings Releases
Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.
“Research and development (R&D) expenses were $15.7 million for the quarter ended March 31, 2023.”
Earnings Releases
Design Therapeutics, Inc. reported for the three months ended March 31, 2023 results: net income Net loss was $19.3 million for the quarter ended March 31, 2023..
“Net loss was $19.3 million for the quarter ended March 31, 2023.”
Earnings Releases
Design Therapeutics, Inc. reported three and twelve months ended December 31, 2022 results: net income Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20.
“On March 14, 2023, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022.”
Earnings Releases
Design Therapeutics, Inc. reported third quarter 2022 results: net income Net loss was $17.7 million.
“Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”
Dawn Giangiulio changed role as Interim Principal Accounting Officer at Design Therapeutics, Inc..
“Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.”
Julie Burgess was appointed as Chief Accounting Officer at Design Therapeutics, Inc..
“On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).”
Dawn Giangiulio was appointed as interim principal accounting officer at Design Therapeutics, Inc..
“Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.”
Justin Thacker resigned as VP, Finance at Design Therapeutics, Inc..
“On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.